Benefits of Levothyroxine Replacement Therapy on Nonalcoholic Fatty Liver Disease in Subclinical Hypothyroidism Patients
Table 3
Change from baseline in metabolic variables in mild SCH patients combined with dyslipidemia.
Variables
Sub-LT4 group ()
Subcontrol group ()
value
Baseline
End-of-study
value#
Baseline
End-of-study
value#
BMI (kg/m2)
26.48 ± 3.13
26.00 ± 3.27
0.001
26.17 ± 3.68
26.20 ± 3.88
0.865
—
Weight (kg)
66.92 ± 10.27
65.44 ± 9.97
<0.001
66.12 ± 11.57
66.12 ± 12.03
0.993
—
TC (mmol/L)
6.27 ± 1.21
5.69 ± 1.15
<0.001
5.99 ± 1.16
5.74 ± 1.14
0.026
—
HDL-C (mmol/L)
1.33 ± 0.36
1.31 ± 0.31
0.301
1.31 ± 0.34
1.42 ± 0.37
<0.001
—
LDL-C (mmol/L)
3.67 ± 0.83
3.43 ± 0.91
<0.001
3.55 ± 0.85
3.35 ± 0.94
0.015
—
Non-HDL-C (mmol/L)
4.93 ± 1.08
4.37 ± 1.03
<0.001
4.68 ± 1.04
4.32 ± 1.02
0.001
—
TG (mmol/L)
1.82 (1.27)
1.49 (1.04)
<0.001
1.84 (1.29)
1.46 (0.90)
<0.001
—
FPG (mmol/L)
6.43 ± 1.54
6.35 ± 1.83
0.329
6.65 ± 2.04
6.50 ± 2.07
0.229
—
Change in TC
−0.58 ± 0.92
−0.25 ± 1.06
0.018
Change in LDL
−0.25 ± 0.63
−0.20 ± 0.77
0.595
Change in Non-HDL-C
−0.56 ± 0.84
−0.36 ± 0.95
0.102
Change in TG
−0.32 (0.88)
−0.34 (0.85)
0.392
Values are expressed as mean ± standard deviation or median (interquartile range). value for comparing variables between sub-LT4 group and subcontrol group. # value for comparing variables between baseline and end-of-study within each group. SCH: subclinical hypothyroidism; LT4: levothyroxine; BMI: body mass index; FPG: fasting plasma glucose; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; non-HDL-C: nonhigh-density lipoprotein cholesterol; TG: triglyceride.
